HUTCHMED (China) Limited announced that updated analysis of the ongoing international Phase I/Ib trial of fruquintinib will be presented at the upcoming 2022 ASCO Gastrointestinal Cancers Symposium, taking place on January 20-22, 2022. The meeting will be held virtually and in person at the Moscone Center in San Francisco, California, US.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
310 GBX | 0.00% | +6.90% | +9.54% |
04-26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
04-26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.54% | 3.32B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- HUTCHMED Limited Update Analysis of Ongoing International Phase I/Ib Trial of Fruquintinib